US6100071A
(en)
*
|
1996-05-07 |
2000-08-08 |
Genentech, Inc. |
Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
|
US7087411B2
(en)
*
|
1999-06-08 |
2006-08-08 |
Regeneron Pharmaceuticals, Inc. |
Fusion protein capable of binding VEGF
|
US7070959B1
(en)
*
|
1999-06-08 |
2006-07-04 |
Regeneron Pharmaceuticals, Inc. |
Modified chimeric polypeptides with improved pharmacokinetic properties
|
WO2005069906A2
(en)
*
|
2004-01-16 |
2005-08-04 |
Yale University |
Methods and compositions relating to vascular endothelial growth factor and th2 mediated inflammatory diseases
|
AU2005222384A1
(en)
|
2004-03-05 |
2005-09-22 |
Vegenics Limited |
Growth factor binding constructs materials and methods
|
JP2008502738A
(ja)
*
|
2004-06-10 |
2008-01-31 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
ヒトの癌を処置するための、vegfインヒビターの使用
|
PL2229956T3
(pl)
|
2004-09-13 |
2013-09-30 |
Genzyme Corp |
Konstrukty multimeryczne
|
US20060134121A1
(en)
*
|
2004-10-29 |
2006-06-22 |
Gavin Thurston |
DII4 antagonists, assays, and therapeutic methods thereof
|
US8048418B2
(en)
|
2004-10-29 |
2011-11-01 |
Regeneron Pharmaceuticals, Inc. |
Therapeutic methods for inhibiting tumor growth with combination of Dll4 antagonists and VEGF antagonists
|
FR2878749B1
(fr)
*
|
2004-12-03 |
2007-12-21 |
Aventis Pharma Sa |
Combinaisons antitumorales contenant en agent inhibiteur de vegt et du 5fu ou un de ses derives
|
JP2008537538A
(ja)
|
2005-02-11 |
2008-09-18 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
Vegf拮抗剤及び降圧剤の治療的組み合わせ
|
ES2548238T3
(es)
*
|
2005-03-25 |
2015-10-15 |
Regeneron Pharmaceuticals, Inc. |
Formulaciones antagonistas de VEGF
|
MX2008001966A
(es)
*
|
2005-08-12 |
2008-03-26 |
Regeneron Pharma |
Tratamiento de enfermedades mediante administracion subcutanea de un antagonista vegf.
|
WO2007041614A2
(en)
*
|
2005-10-03 |
2007-04-12 |
Bolder Biotechnology, Inc. |
Long acting vegf inhibitors and methods of use
|
PL1962895T3
(pl)
*
|
2005-12-16 |
2013-06-28 |
Regeneron Pharma |
Terapeutyczne zastosowanie antagonisty dii4 oraz inhibitora vegf do inhibicji wzrostu nowotworów
|
FR2895258B1
(fr)
*
|
2005-12-22 |
2008-03-21 |
Aventis Pharma Sa |
Combinaison comprenant de la combretastatine et des agents anticancereux
|
CN100502945C
(zh)
*
|
2006-03-31 |
2009-06-24 |
成都康弘生物科技有限公司 |
Vegf受体融合蛋白在治疗眼睛疾病中的应用
|
US8216575B2
(en)
*
|
2006-03-31 |
2012-07-10 |
Chengdu Kanghong Biotechnologies Co., Ltd. |
Inhibition of neovascularization with a soluble chimeric protein comprising VEGF FLT-1 and KDR domains
|
DK2944306T3
(da)
*
|
2006-06-16 |
2021-03-08 |
Regeneron Pharma |
Egnede VEGF-antagonistformuleringer til intravitreal administration
|
WO2008005290A2
(en)
*
|
2006-06-29 |
2008-01-10 |
The Trustees Of Columbia University In The City Of New York |
Methods for testing anti-thrombotic agents
|
WO2008130382A2
(en)
|
2006-10-31 |
2008-10-30 |
East Carolina University |
Fusion proteins comprising an anti -inflammatory cytokine and an antigen for treatment of immune disorders
|
BRPI0812248B8
(pt)
|
2007-06-01 |
2021-05-25 |
Gliknik Inc |
estradômero agrupado
|
TWI436775B
(zh)
|
2007-08-24 |
2014-05-11 |
Oncotherapy Science Inc |
以抗原胜肽合併化療藥劑治療胰臟癌
|
BRPI0910482A2
(pt)
|
2008-04-29 |
2019-09-24 |
Abbott Lab |
imunoglobinas de domínio variável duplo e usos das mesmas
|
JP2011523853A
(ja)
|
2008-06-03 |
2011-08-25 |
アボット・ラボラトリーズ |
二重可変ドメイン免疫グロブリン及びその使用
|
WO2010060748A1
(en)
*
|
2008-11-03 |
2010-06-03 |
Molecular Partners Ag |
Binding proteins inhibiting the vegf-a receptor interaction
|
US9289475B2
(en)
*
|
2008-11-06 |
2016-03-22 |
The Johns Hopkins University |
Treatment of chronic inflammatory respiratory disorders
|
CA2757287C
(en)
|
2009-03-31 |
2019-09-10 |
East Carolina University |
Cytokines and neuroantigens for treatment of immune disorders
|
EP2432476A4
(en)
*
|
2009-05-01 |
2013-03-20 |
Ophthotech Corp |
METHOD FOR THE TREATMENT OR PREVENTION OF EYE DISEASES
|
JO3182B1
(ar)
|
2009-07-29 |
2018-03-08 |
Regeneron Pharma |
مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
|
US8691771B2
(en)
|
2010-05-21 |
2014-04-08 |
Merrimack Pharmaceuticals, Inc. |
Bi-specific fusion proteins for tissue repair
|
UY33492A
(es)
|
2010-07-09 |
2012-01-31 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
WO2012016073A2
(en)
|
2010-07-28 |
2012-02-02 |
Gliknik Inc. |
Fusion proteins of natural human protein fragments to create orderly multimerized immunoglobulin fc compositions
|
CN103298834A
(zh)
|
2010-08-03 |
2013-09-11 |
Abbvie公司 |
双重可变结构域免疫球蛋白及其用途
|
SI2601214T1
(en)
|
2010-08-06 |
2018-03-30 |
Genzyme Corporation |
VEGF antagonist compositions and their use
|
US9518132B2
(en)
*
|
2010-11-09 |
2016-12-13 |
Altimab Therapeutics, Inc. |
Protein complexes for antigen binding and methods of use
|
KR20220097542A
(ko)
|
2011-01-13 |
2022-07-07 |
리제너론 파아마슈티컬스, 인크. |
혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도
|
JO3283B1
(ar)
|
2011-04-26 |
2018-09-16 |
Sanofi Sa |
تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
|
DK2744508T3
(en)
|
2011-08-19 |
2018-02-19 |
Harvard College |
VEGF BINING PROTEIN TO BLOCK ANGIOGENESES
|
SG10201606872TA
(en)
|
2011-08-19 |
2016-10-28 |
Regeneron Pharma |
Anti-tie2 antibodies and uses thereof
|
EP2760893B1
(en)
|
2011-09-30 |
2018-09-12 |
Regeneron Pharmaceuticals, Inc. |
Anti-erbb3 antibodies and uses thereof
|
JO3370B1
(ar)
*
|
2011-11-10 |
2019-03-13 |
Regeneron Pharma |
طريقة لتثبيط نمو الورم عن طريق تثبيط مستقبل انترلوكين 6
|
PT3384903T
(pt)
|
2011-11-18 |
2020-06-25 |
Regeneron Pharma |
Micropartícula contendo proteína terapêutica revestida com polímero biodegradável para uso médico
|
US9988611B2
(en)
*
|
2011-12-01 |
2018-06-05 |
Ap Biosciences, Inc. |
Protein inhibitors to complement and VEGF pathways and methods of use thereof
|
TWI613215B
(zh)
|
2012-02-22 |
2018-02-01 |
再生元醫藥公司 |
抗-大-內皮素-1(big-et-1)抗體及其用途
|
EA036225B1
(ru)
|
2012-03-14 |
2020-10-15 |
Ридженерон Фармасьютикалз, Инк. |
Мультиспецифические антигенсвязывающие молекулы и их применения
|
TWI702955B
(zh)
|
2012-05-15 |
2020-09-01 |
澳大利亞商艾佛蘭屈澳洲私營有限公司 |
使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd)
|
TWI641619B
(zh)
|
2012-06-25 |
2018-11-21 |
美商再生元醫藥公司 |
抗-egfr抗體及其用途
|
CN104718223A
(zh)
|
2012-08-20 |
2015-06-17 |
格利克尼克股份有限公司 |
具有抗原结合和多价FCγ受体结合活性的分子
|
RU2542385C2
(ru)
|
2012-08-31 |
2015-02-20 |
Общество с ограниченной ответственностью "НекстГен" |
Способ получения фармацевтической композиции для индукции развития кровеносных сосудов в тканях, фармацевтическая композиция, полученная этим способом, и способ лечения ишемии тканей и/или органов человека
|
JOP20200236A1
(ar)
|
2012-09-21 |
2017-06-16 |
Regeneron Pharma |
الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
|
BR112015010691A2
(pt)
|
2012-11-13 |
2017-08-22 |
Regeneron Pharma |
Anticorpo que se liga especificamente ao receptor de procineticina (prokr), seu uso no tratamento ou atenuação da dor e composição farmacêutica que o compreende
|
JO3405B1
(ar)
|
2013-01-09 |
2019-10-20 |
Regeneron Pharma |
الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها
|
JP6408492B2
(ja)
|
2013-02-18 |
2018-10-17 |
ヴェジェニクス プロプライエタリー リミテッドVegenics Pty Limited |
リガンド結合分子およびその使用
|
US10377817B2
(en)
|
2013-03-14 |
2019-08-13 |
Regeneron Pharmaceuticals, Inc. |
Human antibodies to GREM1
|
AR095196A1
(es)
|
2013-03-15 |
2015-09-30 |
Regeneron Pharma |
Medio de cultivo celular libre de suero
|
KR102049990B1
(ko)
|
2013-03-28 |
2019-12-03 |
삼성전자주식회사 |
c-Met 항체 및 VEGF 결합 단편이 연결된 융합 단백질
|
MX2016000364A
(es)
|
2013-07-12 |
2016-05-09 |
Ophthotech Corp |
Metodos para tratar o prevenir afecciones oftalmologicas.
|
KR102060187B1
(ko)
|
2013-07-19 |
2019-12-27 |
삼성전자주식회사 |
Vegf-c, vegf-d 및/또는 안지오포이에틴-2를 동시에 저해하는 융합 폴리펩타이드 및 이의 용도
|
WO2015058369A1
(en)
*
|
2013-10-23 |
2015-04-30 |
Sanofi (China) Investment Co., Ltd. |
Use of aflibercept and docetaxel for the treatment of nasopharyngeal carcinoma
|
TWI680138B
(zh)
|
2014-01-23 |
2019-12-21 |
美商再生元醫藥公司 |
抗pd-l1之人類抗體
|
TWI681969B
(zh)
|
2014-01-23 |
2020-01-11 |
美商再生元醫藥公司 |
針對pd-1的人類抗體
|
KR102399005B1
(ko)
|
2014-03-11 |
2022-05-17 |
리제너론 파마슈티칼스 인코포레이티드 |
항-egfrviii 항체 및 그것의 용도
|
KR102288849B1
(ko)
|
2014-03-17 |
2021-08-12 |
애드베룸 바이오테크놀로지스, 인코포레이티드 |
원추세포에서 증강된 유전자 발현을 위한 조성물 및 방법
|
TWI754319B
(zh)
|
2014-03-19 |
2022-02-01 |
美商再生元醫藥公司 |
用於腫瘤治療之方法及抗體組成物
|
CN107076750B
(zh)
|
2014-07-18 |
2020-06-23 |
赛诺菲 |
用于预测疑似患有癌症的患者使用阿柏西普的治疗结果的方法
|
WO2016025645A1
(en)
|
2014-08-12 |
2016-02-18 |
Massachusetts Institute Of Technology |
Synergistic tumor treatment with il-2, a therapeutic antibody, and an immune checkpoint blocker
|
EP3180018B1
(en)
|
2014-08-12 |
2019-07-24 |
Massachusetts Institute Of Technology |
Synergistic tumor treatment with il-2 and integrin-binding-fc-fusion protein
|
PL3221359T3
(pl)
|
2014-11-17 |
2020-11-16 |
Regeneron Pharmaceuticals, Inc. |
Sposoby leczenia nowotworów przy użyciu dwuswoistego przeciwciała CD3XCD20
|
US20160144025A1
(en)
*
|
2014-11-25 |
2016-05-26 |
Regeneron Pharmaceuticals, Inc. |
Methods and formulations for treating vascular eye diseases
|
MY187898A
(en)
|
2015-03-02 |
2021-10-27 |
Adverum Biotechnologies Inc |
Compositions and methods for intravitreal delivery of polynucleotides to retinal cones
|
EP3273998B1
(en)
|
2015-03-27 |
2019-09-04 |
Regeneron Pharmaceuticals, Inc. |
Maytansinoid derivatives, conjugates thereof, and methods of use
|
TWI735433B
(zh)
|
2015-03-27 |
2021-08-11 |
美商再生元醫藥公司 |
偵測生物污染物之組成物及方法
|
BR122022005103B1
(pt)
*
|
2015-04-23 |
2023-03-14 |
Hemanext Inc |
Dispositivo de armazenamento de sangue para armazenar sangue depletado de oxigênio e método para armazenar sangue depletado de oxigênio
|
MA43987A
(fr)
|
2015-05-12 |
2018-12-19 |
Regeneron Pharma |
Détermination de la pureté de protéine multimère
|
RU2612497C2
(ru)
|
2015-05-26 |
2017-03-09 |
Общество с ограниченной ответственностью "НекстГен" |
Оптимизированная нуклеотидная последовательность и фармацевтическая композиция на ее основе с пролонгированной экспрессией трансгена vegf
|
JOP20160154B1
(ar)
|
2015-07-31 |
2021-08-17 |
Regeneron Pharma |
أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها
|
TWI797060B
(zh)
|
2015-08-04 |
2023-04-01 |
美商再生元醫藥公司 |
補充牛磺酸之細胞培養基及用法
|
EA201890785A1
(ru)
|
2015-09-23 |
2018-10-31 |
Ридженерон Фармасьютикалз, Инк. |
Оптимизированные биспецифические анти-cd3 антитела и их применение
|
CA2998390A1
(en)
|
2015-09-28 |
2017-04-06 |
East Carolina University |
Aluminum based adjuvants for tolerogenic vaccination
|
EP3865147A1
(en)
|
2015-10-02 |
2021-08-18 |
Silver Creek Pharmaceuticals, Inc. |
Bi-specific therapeutic proteins for tissue repair
|
TWI756187B
(zh)
|
2015-10-09 |
2022-03-01 |
美商再生元醫藥公司 |
抗lag3抗體及其用途
|
WO2017070866A1
(zh)
*
|
2015-10-28 |
2017-05-04 |
黄志清 |
一种抗血管内皮生长因子的氧化石墨烯与其用途
|
CN108697792A
(zh)
*
|
2015-11-19 |
2018-10-23 |
珠海泰瑞尚生物医药科技有限公司 |
用于结合vegf的方法和组合物
|
KR102343004B1
(ko)
|
2015-12-03 |
2021-12-24 |
리제너론 파마슈티칼스 인코포레이티드 |
항-vegf로 치료된 연령-관련 황반 변성을 앓고 있는 환자에서의 임상 결과와 유전적 변이체를 연관시키는 방법
|
CA3007644A1
(en)
|
2015-12-11 |
2017-06-15 |
Regeneron Pharmaceuticals, Inc. |
Methods for reducing or preventing growth of tumors resistant to egfr and/or erbb3 blockade
|
IL302211A
(en)
|
2015-12-16 |
2023-06-01 |
Regeneron Pharma |
Preparations and methods for making protein microparticles
|
MD3394103T2
(ro)
|
2015-12-22 |
2023-11-30 |
Regeneron Pharma |
Combinație de anticorpi anti-PD-1 și anticorpi bispecifici anti-CD20/anti-CD3 pentru tratamentul cancerului
|
GB2545763A
(en)
|
2015-12-23 |
2017-06-28 |
Adverum Biotechnologies Inc |
Mutant viral capsid libraries and related systems and methods
|
KR20180099892A
(ko)
|
2016-01-25 |
2018-09-05 |
리제너론 파아마슈티컬스, 인크. |
메이탄시노이드 유도체, 그의 접합체, 및 사용 방법
|
WO2017190079A1
(en)
|
2016-04-28 |
2017-11-02 |
Regeneron Pharmaceuticals, Inc. |
Methods of making multispecific antigen-binding molecules
|
CA3022600A1
(en)
|
2016-04-29 |
2017-11-02 |
Adverum Biotechnologies, Inc. |
Evasion of neutralizing antibodies by a recombinant adeno-associated virus
|
TWI822521B
(zh)
|
2016-05-13 |
2023-11-11 |
美商再生元醫藥公司 |
藉由投予pd-1抑制劑治療皮膚癌之方法
|
WO2017214321A1
(en)
|
2016-06-07 |
2017-12-14 |
Gliknik Inc. |
Cysteine-optimized stradomers
|
AU2017278193B9
(en)
|
2016-06-10 |
2024-02-01 |
Regeneron Pharmaceuticals, Inc. |
Anti-GITR antibodies and uses thereof
|
CN117593362A
(zh)
|
2016-07-29 |
2024-02-23 |
里珍纳龙药品有限公司 |
具有集成电子视觉检查的组装线
|
EA201990317A1
(ru)
|
2016-08-16 |
2019-07-31 |
Ридженерон Фармасьютикалз, Инк. |
Способы определения количества индивидуальных антител из смеси
|
FI3761035T3
(fi)
|
2016-08-18 |
2024-03-18 |
Regeneron Pharma |
Analyysi proteiinin itseassosiaatiomahdollisuuden määrittämiseksi käyttäen pitoisuudesta riippuvaa itseinteraktio-nanopartikkelispektroskopiaa
|
EP3504328A1
(en)
|
2016-08-24 |
2019-07-03 |
Regeneron Pharmaceuticals, Inc. |
Host cell protein modification
|
CA3037732A1
(en)
|
2016-09-23 |
2018-03-29 |
Regeneron Pharmaceuticals, Inc. |
Anti-steap2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind steap2 and cd3, and uses thereof
|
IL265309B2
(en)
|
2016-09-23 |
2024-04-01 |
Regeneron Pharma |
Bispecific antibodies against MUC16 and antibodies against MUC16 for use in cancer treatment
|
BR112019006907A2
(pt)
|
2016-10-07 |
2019-07-02 |
Regeneron Pharma |
proteína liofilizada estável em temperatura ambiente
|
AU2017345470B2
(en)
|
2016-10-19 |
2023-08-03 |
Adverum Biotechnologies, Inc. |
Modified AAV capsids and uses thereof
|
ES2924060T3
(es)
|
2016-10-25 |
2022-10-04 |
Regeneron Pharma |
Procedimientos y sistema para análisis de datos de cromatografía
|
TWI782930B
(zh)
|
2016-11-16 |
2022-11-11 |
美商再生元醫藥公司 |
抗met抗體,結合met之雙特異性抗原結合分子及其使用方法
|
US11135266B2
(en)
|
2016-11-21 |
2021-10-05 |
Just-Evotec Biologics, Inc. |
Aflibercept formulations and uses thereof
|
US10925971B2
(en)
|
2016-11-29 |
2021-02-23 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating PRLR positive breast cancer
|
WO2018107079A1
(en)
|
2016-12-09 |
2018-06-14 |
Gliknik Inc. |
Manufacturing optimization of gl-2045, a multimerizing stradomer
|
CA3049656A1
(en)
|
2017-01-10 |
2018-07-19 |
Nodus Therapeutics |
Combination tumor treatment with an integrin-binding-fc fusion protein and immune modulator
|
US10350266B2
(en)
|
2017-01-10 |
2019-07-16 |
Nodus Therapeutics, Inc. |
Method of treating cancer with a multiple integrin binding Fc fusion protein
|
KR20240058959A
(ko)
|
2017-02-10 |
2024-05-07 |
리제너론 파마슈티칼스 인코포레이티드 |
면역-pet 이미지화를 위한 방사선 라벨링된 항-lag3 항체
|
JP7324710B2
(ja)
|
2017-02-21 |
2023-08-10 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
肺癌の処置のための抗pd-1抗体
|
US11773406B2
(en)
|
2017-03-17 |
2023-10-03 |
Adverum Biotechnologies, Inc. |
Compositions and methods for enhanced gene expression
|
US11603407B2
(en)
|
2017-04-06 |
2023-03-14 |
Regeneron Pharmaceuticals, Inc. |
Stable antibody formulation
|
AU2018266324B2
(en)
|
2017-05-06 |
2024-02-01 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating eye disorders with APLNR antagonists and VEGF inhibitors
|
US10806780B2
(en)
|
2017-06-28 |
2020-10-20 |
Regeneron Pharmaceuticals, Inc. |
Anti-human papillomavirus (HPV) antigen-binding proteins and methods of use thereof
|
KR20210084695A
(ko)
|
2017-07-06 |
2021-07-07 |
리제너론 파마슈티칼스 인코포레이티드 |
당단백질을 만들기 위한 세포 배양 과정
|
BR112020001360A2
(pt)
|
2017-07-24 |
2020-08-11 |
Regeneron Pharmaceuticals, Inc. |
anticorpo monoclonal isolado ou fragmento de ligação a antígeno deste que se liga a cd8, composição farmacêutica, molécula de ácido nucleico, vetor de expressão, célula hospedeira, conjugado de anticorpo, métodos para gerar imagens de um tecido que expressa cd8, para tratar um sujeito tendo um tumor sólido, para prever uma resposta positiva a uma terapia antitumoral, para monitorar uma resposta de um tumor em um sujeito a uma terapia antitumoral, para prever ou monitorar a eficácia da terapia antitumoral e para monitorar a presença de células t em um tumor ao longo do tempo, e, composto.
|
TWI799432B
(zh)
|
2017-07-27 |
2023-04-21 |
美商再生元醫藥公司 |
抗ctla-4抗體及其用途
|
WO2019075270A1
(en)
|
2017-10-12 |
2019-04-18 |
Amesino Llc |
VEGFR ANTIBODY LIGHT CHAIN FUSION PROTEIN
|
AU2018350990A1
(en)
*
|
2017-10-18 |
2020-05-21 |
Regenxbio Inc. |
Treatment of ocular diseases and metastatic colon cancer with human post-translationally modified VEGF-Trap
|
CN111465407A
(zh)
|
2017-11-30 |
2020-07-28 |
瑞泽恩制药公司 |
使用vegf拮抗剂治疗生血管性眼病
|
BR112020011072A2
(pt)
|
2017-12-13 |
2020-11-17 |
Regeneron Pharmaceuticals, Inc. |
dispositivos e sistemas para gerenciamento de suporte de leito de coluna cromatográfica e métodos relacionados
|
CA3084059A1
(en)
|
2017-12-22 |
2019-06-27 |
Regeneron Pharmaceuticals, Inc. |
System and method for characterizing drug product impurities
|
JP2021511061A
(ja)
|
2018-01-26 |
2021-05-06 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
抗vegf剤を使用した血管新生障害の治療のための方法および組成物
|
US20190234959A1
(en)
|
2018-01-31 |
2019-08-01 |
Regeneron Pharmaceuticals, Inc. |
System and method for characterizing drug product impurities
|
TWI825066B
(zh)
|
2018-02-01 |
2023-12-11 |
美商再生元醫藥公司 |
治療性單株抗體之品質屬性的定量及模型化
|
TW202311746A
(zh)
|
2018-02-02 |
2023-03-16 |
美商再生元醫藥公司 |
用於表徵蛋白質二聚合之系統及方法
|
US20190264293A1
(en)
|
2018-02-28 |
2019-08-29 |
Regeneron Pharmaceuticals, Inc. |
Systems and methods for identifying viral contaminants
|
BR112020015291B1
(pt)
|
2018-03-19 |
2023-09-26 |
Regeneron Pharmaceuticals, Inc |
Tampão de amostra de eletroforese aquoso, método para identificar contaminantes ou impurezas em uma amostra de fármaco proteico, e, kit
|
US20210113615A1
(en)
|
2018-04-13 |
2021-04-22 |
Ludwig Institute For Cancer Research Ltd. |
Heterodimeric inactivatable chimeric antigen receptors
|
MX2020011487A
(es)
|
2018-04-30 |
2020-12-07 |
Regeneron Pharma |
Anticuerpos y moleculas biespecificas de union al antigeno que se unen a her2 y/o aplp2, conjugados y usos de estos.
|
TW202348297A
(zh)
|
2018-05-02 |
2023-12-16 |
美商里珍納龍藥品有限公司 |
用於評估生化過濾器的適合性的方法
|
WO2019217927A1
(en)
|
2018-05-10 |
2019-11-14 |
Regeneron Pharmaceuticals, Inc. |
High concentration vegf receptor fusion protein containing formulations
|
TW202016125A
(zh)
|
2018-05-10 |
2020-05-01 |
美商再生元醫藥公司 |
用於定量及調節蛋白質黏度之系統與方法
|
US11519020B2
(en)
|
2018-05-25 |
2022-12-06 |
Regeneron Pharmaceuticals, Inc. |
Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
|
TW202005985A
(zh)
|
2018-06-21 |
2020-02-01 |
美商再生元醫藥公司 |
用雙特異性抗CD3xMUC16抗體及抗PD-1抗體治療癌症的方法
|
TW202005694A
(zh)
|
2018-07-02 |
2020-02-01 |
美商里珍納龍藥品有限公司 |
自混合物製備多肽之系統及方法
|
WO2020036845A1
(en)
|
2018-08-13 |
2020-02-20 |
Regeneron Pharmaceuticals, Inc. |
Therapeutic protein selection in simulated in vivo conditions
|
BR112020026348A2
(pt)
|
2018-08-30 |
2021-03-30 |
Regeneron Pharmaceuticals, Inc. |
Método para avaliar a estequiometria e distribuição de tamanho de complexos de proteínas, para selecionar um medicamento de proteína principal e para caracterizar complexos de proteínas, e, composição farmacêutica
|
KR20210093908A
(ko)
|
2018-10-23 |
2021-07-28 |
리제너론 파아마슈티컬스, 인크. |
Ny-eso-1 t 세포 수용체 및 이의 사용 방법
|
WO2020150492A1
(en)
|
2019-01-16 |
2020-07-23 |
Regeneron Pharmaceuticals, Inc. |
Methods for identifying free thiols in proteins
|
EP3914914A1
(en)
|
2019-01-25 |
2021-12-01 |
Regeneron Pharmaceuticals, Inc. |
Protein a chromatography - electrospray ionization mass spectrometer
|
CA3126719A1
(en)
|
2019-01-25 |
2020-07-30 |
Regeneron Pharmaceuticals, Inc. |
Quantitation and identification of dimers in co-formulations
|
CA3127696A1
(en)
|
2019-02-12 |
2020-08-20 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for using bispecific antibodies to bind complement and a target antigen
|
WO2020172475A1
(en)
|
2019-02-21 |
2020-08-27 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating ocular cancer using anti-met antibodies and bispecific antigen binding molecules that bind met
|
JP2022523804A
(ja)
|
2019-03-06 |
2022-04-26 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
がんの処置における増強された有効性のためのil-4/il-13経路阻害剤
|
EA202192850A1
(ru)
|
2019-04-17 |
2022-01-26 |
Ридженерон Фармасьютикалз, Инк. |
Идентификация белков клетки-хозяина
|
US10961500B1
(en)
|
2019-04-23 |
2021-03-30 |
Regeneron Pharmaceuticals, Inc. |
Cell culture medium for eukaryotic cells
|
TW202106699A
(zh)
|
2019-04-26 |
2021-02-16 |
美商愛德維仁生物科技公司 |
用於玻璃體內遞送之變異體aav蛋白殼
|
EP3969908A1
(en)
|
2019-05-13 |
2022-03-23 |
Regeneron Pharmaceuticals, Inc. |
Improved competitive ligand binding assays
|
JP2022532490A
(ja)
|
2019-05-13 |
2022-07-15 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
癌の治療における有効性の増強のためのpd-1阻害剤とlag-3阻害剤の組み合わせ
|
AU2020296181A1
(en)
|
2019-06-21 |
2021-12-16 |
Regeneron Pharmaceuticals, Inc. |
Use of bispecific antigen-binding molecules that bind PSMA and CD3 in combination with 4-1BB co-stimulation
|
MA56537A
(fr)
|
2019-06-21 |
2022-04-27 |
Regeneron Pharma |
Utilisation de molécules de liaison à l'antigène bispécifiques qui se lient à muc16 et cd3 en combinaison avec une co-stimulation de 4-1bb
|
CN110343666B
(zh)
*
|
2019-07-10 |
2023-05-30 |
通化东宝药业股份有限公司 |
一种cho细胞培养的补料培养基及其制备方法和应用
|
EP4031574A1
(en)
|
2019-09-16 |
2022-07-27 |
Regeneron Pharmaceuticals, Inc. |
Radiolabeled met binding proteins for immuno-pet imaging
|
US11814428B2
(en)
|
2019-09-19 |
2023-11-14 |
Regeneron Pharmaceuticals, Inc. |
Anti-PTCRA antibody-drug conjugates and uses thereof
|
JP2022548394A
(ja)
|
2019-09-24 |
2022-11-18 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
クロマトグラフィーの使用および再生のためのシステムおよび方法
|
CA3157509A1
(en)
|
2019-10-10 |
2021-04-15 |
Kodiak Sciences Inc. |
Methods of treating an eye disorder
|
MX2022006241A
(es)
|
2019-11-25 |
2022-08-22 |
Univ California |
Inhibidores de vegf de accion prolongada para la neovascularizacion intraocular.
|
JP2023502500A
(ja)
|
2019-11-25 |
2023-01-24 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
非水性エマルションを使用した持続放出製剤
|
WO2021113591A1
(en)
*
|
2019-12-06 |
2021-06-10 |
Regeneron Pharmaceuticals, Inc. |
Vegf mini-traps and methods of use thereof
|
AU2020397803C1
(en)
|
2019-12-06 |
2023-05-11 |
Regeneron Pharmaceuticals, Inc. |
Anti-VEGF protein compositions and methods for producing the same
|
US20230141511A1
(en)
|
2019-12-20 |
2023-05-11 |
Ludwig Institute For Cancer Research Ltd |
Car-t cell therapy targeting ngcgm3
|
IL294765B2
(en)
|
2020-01-21 |
2023-12-01 |
Regeneron Pharma |
Deglycosylation methods for electrophoresis of glycosylated proteins
|
MX2022009137A
(es)
|
2020-01-24 |
2022-10-21 |
Regeneron Pharma |
Antígeno expresado preferentemente en receptores de linfocitos t de melanoma (prame) y sus métodos de uso.
|
US20210270824A1
(en)
|
2020-02-27 |
2021-09-02 |
Regeneron Pharmaceuticals, Inc. |
Activity based host cell protein profiling
|
CN115175737A
(zh)
|
2020-02-28 |
2022-10-11 |
瑞泽恩制药公司 |
结合her2的双特异性抗原结合分子及其使用方法
|
AU2021232041A1
(en)
|
2020-03-06 |
2022-09-08 |
Regeneron Pharmaceuticals, Inc. |
Anti-GITR antibodies and uses thereof
|
JP2023519961A
(ja)
|
2020-03-30 |
2023-05-15 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
低存在量の宿主細胞タンパク質を特徴付けるための方法
|
AU2021268026A1
(en)
*
|
2020-05-08 |
2023-01-19 |
Regeneron Pharmaceuticals, Inc. |
VEGF traps and mini-traps and methods for treating ocular disorders and cancer
|
CN115734971A
(zh)
|
2020-06-22 |
2023-03-03 |
信达生物制药(苏州)有限公司 |
抗ang-2抗体及其用途
|
KR20230038738A
(ko)
|
2020-07-13 |
2023-03-21 |
리제너론 파마슈티칼스 인코포레이티드 |
단백질에서 글루타민 잔기에 접합된 캄토테신 유사체 및 그의 용도
|
WO2022014707A1
(ja)
|
2020-07-16 |
2022-01-20 |
ラクオリア創薬株式会社 |
眼疾患の治療薬としてのtrpv4阻害薬
|
UY39324A
(es)
|
2020-07-16 |
2022-02-25 |
Novartis Ag |
Anticuerpos anti-betacelulina, sus fragmentos, moléculas de unión multiespecíficas, casetes de expresión, composiciones y métodos de tratamiento.
|
AU2021332355A1
(en)
|
2020-08-31 |
2023-03-23 |
Regeneron Pharmaceuticals, Inc. |
Asparagine feed strategies to improve cell culture performance and mitigate asparagine sequence variants
|
US20230374160A1
(en)
|
2020-10-02 |
2023-11-23 |
Regeneron Pharmaceuticals, Inc. |
Combination of antibodies for treating cancer with reduced cytokine release syndrome
|
CA3190569A1
(en)
|
2020-10-22 |
2022-04-28 |
Christopher Daly |
Anti-fgfr2 antibodies and methods of use thereof
|
CA3198294A1
(en)
|
2020-11-10 |
2022-05-19 |
Thomas Nittoli |
Selenium antibody conjugates
|
WO2022115588A1
(en)
|
2020-11-25 |
2022-06-02 |
Regeneron Pharmaceuticals, Inc. |
Sustained release formulations using non-aqueous membrane emulsification
|
AU2021401301A1
(en)
|
2020-12-17 |
2023-08-03 |
Regeneron Pharmaceuticals, Inc. |
Fabrication of protein-encapsulating microgels
|
TW202233827A
(zh)
|
2021-01-20 |
2022-09-01 |
美商再生元醫藥公司 |
改良細胞培養中蛋白質效價的方法
|
BR112023014337A8
(pt)
|
2021-01-25 |
2024-03-05 |
Regeneron Pharma |
Anticorpos anti-pdgf-b e métodos de uso para tratar hipertensão arterial pulmonar (pah)
|
US20240034796A1
(en)
|
2021-02-04 |
2024-02-01 |
Genuv Inc. |
Anti-pd-1 antibody and use thereof
|
AU2022219955A1
(en)
|
2021-02-11 |
2023-09-21 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating cancer by administering a neoadjuvant pd-1 inhibitor
|
KR20230159833A
(ko)
|
2021-02-23 |
2023-11-22 |
리제너론 파마슈티칼스 인코포레이티드 |
Pd-1 저해제의 투여에 의한 폐암 치료 방법
|
US20220404369A1
(en)
|
2021-03-03 |
2022-12-22 |
Regeneron Pharmaceuticals, Inc. |
Systems and methods for quantifying and modifying protein viscosity
|
JP2024511106A
(ja)
|
2021-03-23 |
2024-03-12 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
Pd-1阻害剤を投与することにより免疫抑制または免疫不全患者におけるがんを処置する方法
|
IL305731A
(en)
|
2021-03-26 |
2023-11-01 |
Regeneron Pharma |
Methods and systems for developing mixing protocols
|
EP4349852A1
(en)
|
2021-05-28 |
2024-04-10 |
Shanghai Regenelead Therapies Co., Ltd. |
Recombinant adeno-associated virus having variant capsid, and application thereof
|
WO2022256383A1
(en)
|
2021-06-01 |
2022-12-08 |
Regeneron Pharmaceuticals, Inc. |
Micropchip capillary electrophoresis assays and reagents
|
KR20240024061A
(ko)
|
2021-06-22 |
2024-02-23 |
리제너론 파마슈티칼스 인코포레이티드 |
항-EGFRvIII 항체 약물 접합체 및 이의 용도
|
US20230018713A1
(en)
|
2021-07-13 |
2023-01-19 |
Regeneron Pharmaceuticals, Inc. |
Characterization of proteins by anion-exchange chromatography mass spectrometry (aex-ms)
|
EP4370929A1
(en)
|
2021-07-13 |
2024-05-22 |
Regeneron Pharmaceuticals, Inc. |
Mass spectrometry-based strategy for determining product-related variants of a biologic
|
AR127006A1
(es)
|
2021-09-08 |
2023-12-06 |
Regeneron Pharma |
UN MÉTODO BASADO EN ESPECTROMETRÍA DE MASAS Y DE ALTO RENDIMIENTO PARA CUANTIFICAR ANTICUERPOS Y OTRAS PROTEÍNAS QUE CONTIENEN Fc
|
WO2023043733A1
(en)
|
2021-09-14 |
2023-03-23 |
Regeneron Pharmaceuticals, Inc. |
Nmass spectrometry-based strategy for characterizing high molecular weight species of a biologic
|
WO2023055808A1
(en)
|
2021-09-28 |
2023-04-06 |
Regeneron Pharmaceuticals, Inc. |
Assays to quantitate drug and target concentrations
|
CA3230984A1
(en)
|
2021-10-07 |
2023-04-13 |
Ross BROWNE |
Systems and methods of ph modeling and control
|
IL311248A
(en)
|
2021-10-07 |
2024-05-01 |
Regeneron Pharma |
PH meter calibration and repair
|
US20230129265A1
(en)
|
2021-10-26 |
2023-04-27 |
Regeneron Pharmaceuticals, Inc. |
Systems and methods for generating laboratory water and distributing laboratory water at different temperatures
|
AU2022375710A1
(en)
|
2021-11-01 |
2024-05-02 |
Regeneron Pharmaceuticals, Inc. |
Methods to prevent disulfide scrambling for ms-based proteomics
|
WO2023081925A1
(en)
|
2021-11-08 |
2023-05-11 |
Immatics Biotechnologies Gmbh |
Adoptive cell therapy combination treatment and compositions thereof
|
WO2023097030A1
(en)
|
2021-11-24 |
2023-06-01 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating cancer with bispecific anti-cd3 x muc16 antibodies and anti-ctla-4 antibodies
|
AR127806A1
(es)
|
2021-12-01 |
2024-02-28 |
Kadmon Corp Llc |
Anticuerpos b7-h4 y proteínas de fusión de anticuerpo b7-h4 / il-15
|
US20230287138A1
(en)
|
2022-01-12 |
2023-09-14 |
Regneron Pharmaceuticals, Inc. |
Protein-drug conjugates comprising camptothecin analogs and methods of use thereof
|
TW202346856A
(zh)
|
2022-03-18 |
2023-12-01 |
美商里珍納龍藥品有限公司 |
分析多肽變體的方法及系統
|
WO2023196903A1
(en)
|
2022-04-06 |
2023-10-12 |
Regeneron Pharmaceuticals, Inc. |
Bispecific antigen-binding molecules that bind and cd3 and tumor associated antigens (taas) and uses thereof
|
WO2023240109A1
(en)
|
2022-06-07 |
2023-12-14 |
Regeneron Pharmaceuticals, Inc. |
Multispecific molecules for modulating t-cell activity, and uses thereof
|
WO2024097642A1
(en)
|
2022-10-31 |
2024-05-10 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating cancer with a combination of adoptive cell therapy and a targeted immunocytokine
|